drugs
CT healthcare costs grew faster than ever in 2023, but Medicaid bucked the trend
Download the analysis This month, the Office of Health Strategy (OHS) released their three annual Healthcare Benchmark reports. The main event, the Cost Growth Benchmark Report, finds that healthcare costs rose by 7.8% in 2023, well above the 2.9% benchmark set by an old OHS committee based on economic indicators. This is the third year…
Read MoreNutrition initiative could save $908 million per year in CT healthcare spending – Potential Medicaid LTC spending relief option
Medically tailored meals (MTMs) could save Connecticut $6,299 net per year per person, by far the highest savings among states, according to a new study published in Health Affairs. This research offers an important option to address Connecticut Medicaid long-term care costs that not only saves money, but also improves health. MTMs are nutritious, prepared…
Read MoreJust a sample of Trump healthcare news
I’ve been avoiding writing about the impact of the Trump administration’s policies on healthcare. It’s overwhelming and it changes daily. But waiting for it to settle out isn’t working. It’s time to dig in. Reporters, in Connecticut and nationally, are doing an exceptional job of documenting this as it happens. Here are a small sample…
Read MoreHUSKY still very efficient but drugs are driving up costs
Read the full report Like other states, Connecticut Medicaid per member costs are beginning to increase after dropping during COVID. However, Connecticut’s rate trend remains better than other states. Since switching from managed care organizations in 2012 to focus on care management, Connecticut Medicaid spending stabilized while enrollment expanded significantly, according to the state’s latest…
Read MoreDSS’s comprehensive HUSKY report finds a very strong program, with plans to improve
In response to 2023 legislation, on Tuesday DSS provided a 72-page comprehensive description and analysis of Connecticut’s Medicaid program to MAPOC, the program’s oversight council. The report also includes DSS’s strategy to improve the program and members’ health. The report finds that the program’s performance is very strong. “Overall, the Medicaid program achieves good quality…
Read MoreAnalysis: Trump order jeopardizes cost effective, life-changing cure for sickle cell
We are lucky to live in a time when creative scientists are developing life-changing new cures for debilitating genetic diseases. These breakthrough treatments are as important as penicillin or insulin were in their time. Unfortunately, they are also very expensive. To help pay for them, federal Medicaid officials created an opportunity to help states afford…
Read MoreWandering around in OHS’s databases – lots to learn and a surprise
Our state Office of Health Strategy has several impressive portals and dashboards to explore their trove of data and other information. They include healthcare affordability, ED visits, quality ratings, facility plans, self-sufficiency tools, hospital finances, prescription drug costs, and Race, ethnicity and language data. Visitors can sort the data by service, payer, age, gender, and…
Read MoreICER’s 4th annual report finds progress in fair access to prescription drugs
Over the last four years, barriers facing patients getting access to cost effective drugs in commercial plans and the Veteran’s Administration have gotten better, according to ICER’s fourth annual Barriers to Fair Access report. The authors compare plan policies, including cost sharing, clinical eligibility, step therapy and provider restrictions, to independent standards for fair access…
Read MoreReport finds growing number of drug prices rising without merit
Half of the ten fastest-rising drug prices without any evidence of improved value last year, according to the latest report from ICER. This is the highest percentage of unsupported prescription drug prices since ICER began this report in 2019. The increased prices rose far faster than inflation for the rest of the economy. Just the…
Read MoreAnalysis: DSS Study Suggests MCOs don’t Make Sense for HUSKY
Last Friday, the state released a consultants’ report exploring the Governor’s controversial plan to bring private insurers back to run Medicaid in Connecticut. The report’s authors agree with advocates that there is no evidence that MCOs control costs or improve quality or access to care. They also agree that HUSKY, our state Medicaid program, is…
Read More